Triple Marker – Second Trimester – Maternal Screen 3

Between 15 to 21 weeks of pregnancy, expecting mothers often undergo the essential prenatal screening test known as Triple Marker – Second Trimester – Maternal Screen 3. This test helps doctors assess the likelihood of chromosomal disorders in the developing fetus, such as Down syndrome (Trisomy 21) and Edward syndrome (Trisomy 18) and spina bifida neural tube defects.

Triple Marker Test Includes:

It measures three essential substances present in maternal blood to determine results.

• Alpha-fetoprotein (AFP) – a protein produced by the fetus’s liver
• Human Chorionic Gonadotropin (hCG) – a hormone secreted by the placenta
• Unconjugated Estriol (uE3) – an estrogen synthesized by both the fetus and the placenta

The test assesses the risk of neural tube and chromosomal abnormality through blood substance measurements in the mother’s blood.

The Triple Marker test is advised for:

• All pregnant women between 15–21 weeks of gestation
• Women over age 35 or those with a family history of genetic conditions
• Pregnant women who missed first-trimester screening

The test functions as a non-invasive method to direct additional diagnostic examinations such as amniocentesis or ultrasound when required.

 UniQ Pathlab offers Triple Marker – Second Trimester – Maternal Screen 3 testing service at a reasonable price, you can easily book an appointment for expert pregnancy assessment with free home collection and fast report turnaround—supporting informed and safe pregnancy decisions.